Shots: Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label […]readmore
Tags : Relapsing-Remitting
Shots: The approval is based on the results of P-III PARADIGMS study assessing Gilenya (0.5mg/ 0.25mg, qd) vs Extavia (interferon beta-1a, qw) in 215 patients with MS aged 10 to […]readmore